Senators set to debate Obamacare replacement

26 July 2017

The Republicans finally took a step towards achieving President Donald Trump’s key campaign pledge of replacing the Affordable Care Act (ACA) on Tuesday evening, though only by convincing Senators to debate the issue.

A decisive vote from Vice President Mike Pence was needed to allow the discussion on health care legislation to take place, with previous attempts by the Trump administration to repeal and replace the ACA, known as Obamacare due its introduction by previous President Barack Obama, having failed.

And after the vote to begin debate, the Senate considered a comprehensive replacement for the ACA that would have cut health insurance and subsidies for lower income groups, but that fell far short of the support it needed to pass.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK